Open webinar: How can SciLifeLab, MAX IV and ESS contribute to drug discovery and development?
During this seminar the three large-scale research infrastructures – SciLifeLab, MAX IV and ESS – will present their offer to the Life Science industry in form of advanced technologies in the shape of research infrastructure, as well as relevant data support and structures. Together they can provide technologies ranging from genomics, proteomics, genome engineering and drug discovery, to X-ray beamlines and the most powerful neutron source worldwide.
The webinar is a joint venture between Lif and InfraLife, the initiative that serve as a hub
connecting stakeholders, displaying the potential of the advanced technologies, and making these unprecedented tools accessible to be utilized in addressing complex research questions.
Who should attend?
Everyone who works within pharma industry and the Life Science-ecosystem in Sweden and is
curious about what services these three major national infrastructures can offer and how to start
a research project.
Frida Lundmark, Lif
The InfraLife project
Elin Jonsson and Josefin Lundgren Gawell, project coordinators InfraLife
SciLifeLab – possibilities in drug discovery & Development
Per Arvidsson, Director Drug Discovery & Development platform, SciLifeLab
Cryo-EM recent development and great possibilities for drug research
Marta Carroni, Platform Director, Cell and Molecular Imaging, SciLifeLab
The MAX IV synchrotron and possibilities for Life Science
Selma Maric, Industrial Relations, Life Science and Soft Matter, MAX IV
Neutron research possibilities for drug development and the European Spallation Source (ESS)
Zoë Fisher, Group Leader for Deuteration and Macromolecular Crystallisation, ESS
Industry examples from X-ray and neutron experiments
Emanuel Larsson, Postdoctoral fellow, Solid Mechanics, Expert Lunarc (Centre for Scientific and Technological Computing), Lund University
Time for questions
Wrap up and future perspectives